Translational efficacy of humanized exposures of cefepime, ertapenem, and levofloxacin against extended-spectrum-β-lactamase-producing Escherichia coli in a murine model of complicated urinary tract infection

Marguerite L. Monogue, David P. Nicolaua

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Validated animal models are required as bridging tools to assess the utility of novel therapies and potential microbiologic outcomes. Herein, we utilized uropathogenic extended-spectrum-β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in the neutropenic murine complicated urinary tract infection (cUTI) model with humanized exposures of cefepime, ertapenem, and levofloxacin to assess its translational value to human outcomes. Our data support the translational utility of this murine model to cUTI in humans as humanized exposures produced microbiologic outcomes consistent with the phenotypic profiles of the organisms.

Original languageEnglish (US)
Article numbere01329-17
JournalAntimicrobial Agents and Chemotherapy
Volume61
Issue number11
DOIs
StatePublished - Nov 2017
Externally publishedYes

Keywords

  • Cefepime
  • Ertapenem
  • ESBL
  • Escherichia coli
  • Levofloxacin
  • Urinary tract infection

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Translational efficacy of humanized exposures of cefepime, ertapenem, and levofloxacin against extended-spectrum-β-lactamase-producing Escherichia coli in a murine model of complicated urinary tract infection'. Together they form a unique fingerprint.

  • Cite this